Introduction
Prostate cancer is one of the most common cancers affecting men. While many prostate cancers respond to treatments that lower testosterone levels, some cancers eventually continue growing despite reduced hormone levels, while others have already spread beyond the prostate at the time treatment begins. In these situations, additional therapies that directly block androgen receptor signaling may help slow disease progression.
Nubeqa is a targeted hormonal therapy used alongside androgen deprivation therapy (ADT) for certain patients with non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer. By preventing androgens from activating prostate cancer
Prescription Hope helps patients access affordable brand-name medications at a fraction of the medication’s retail cost.
What Is the Nubeqa Patient Assistance Program?
Understanding Nubeqa Prescription Assistance
Nubeqa is offered through a patient assistance program at an affordable rate.
But what is a patient assistance program?
Due to rising retail costs of brand-name medications, manufacturers often offer patient assistance programs. Through these, qualified patients get access to the manufacturer’s brand-name medication at an affordable rate.
However, many programs require extensive application processes that leave patients across the nation feeling overwhelmed and frustrated. With requirements that include consistent contact with the manufacturer, extensive documentation, completing forms without any errors or inaccuracies, gathering required signatures from healthcare providers, and more, patients look for assistance.
Prescription Hope can help.
How Expert Advocates Help Make Nubeqa More Affordable
Personalized Medication Assistance
Getting prostate cancer medication support through a patient assistance program can be extremely beneficial for patients. Prescription Hope’s team of patient advocates supports patients from start to finish, helping them not only apply but manage their patient assistance program enrollment status.
Ongoing Patient Support
After approval and the initial medication ships, Prescription Hope continues to support you throughout your medication access journey.
Our patient assistance specialists manage form and document updates, issue resolution, yearly renewals, and even take care of your refill schedule.
Navigating Specialty Medication Costs
While medication costs continue to put a burden on the finances of many patients, Prescription Hope’s services remain a trusted solution. Our service rate of $70.00 per month, per medication means qualified patients do not see hidden fees, add-on charges, or medication costs.
And if we can’t help you save, then you pay nothing!
Nubeqa Patient Assistance Eligibility
General Eligibility Requirements
Wondering who qualifies for Nubeqa assistance? Enroll with Prescription Hope to find out more about Nubeqa eligibility.
Meanwhile, patients should understand that all patient assistance programs maintain strict approval requirements. While specific requirements differ, all programs typically use several general categories to determine a patient’s qualification:
Income: All programs use income as a criterion, but each program’s income range differs.
Insurance: Each program maintains its own insurance coverage status requirements.
Prescription: All programs require a valid prescription for the medication a patient applies for.
U.S. Residency: All programs require qualified patients to be legal U.S. residents.
Simple Enrollment With Expert Support
Getting Started With Enrollment
Ready to get started? Looking to enroll in Nubeqa assistance?
Follow Prescription Hope’s 6 simple steps:
- Submit Information: Complete our online form. It only takes a few minutes.
- Advocate Contact: After you complete our form, a patient advocate will contact you within 1-2 business days.
- Document Collection: Once you pass a quick prequalification, our team collects all necessary documents.
- Provider Coordination: We also gather required signatures from your healthcare provider.
- Program Submission: We submit your completed application to the manufacturer and continue to follow up throughout the processing stage.
- Medication Delivery: After approval, qualified patients typically receive their medication within 2 weeks. All medication ships directly from the manufacturer to the patient’s door or doctor’s office.
Prescription Hope is not a pharmacy or manufacturer. We do not handle medication at any time.
Understanding Nubeqa
How Nubeqa Works
Nubeqa contains darolutamide, a nonsteroidal androgen receptor inhibitor.
Prostate cancer cells often rely on male hormones (androgens), such as testosterone, to grow and survive. Darolutamide binds to androgen receptors and blocks androgen signaling, thereby inhibiting androgen receptor signaling that promotes prostate cancer cell growth and survival.
Unlike testosterone-lowering therapies, darolutamide does not reduce androgen production. Instead, it prevents androgens from stimulating prostate cancer cells. It is used together with androgen deprivation therapy (ADT), which lowers testosterone production.
What Conditions Does Nubeqa Treat?
Nubeqa is FDA-approved for the treatment of:
- Metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT), with or without docetaxel as indicated
- Non-metastatic castration-resistant prostate cancer (nmCRPC) in combination with androgen deprivation therapy (ADT)
Nubeqa is used as part of combination therapy to slow disease progression in prostate cancer that continues to depend on androgen receptor signaling.
Benefits of Treatment
For appropriate patients with prostate cancer, Nubeqa may:
- Delay disease progression in non-metastatic castration-resistant prostate cancer
- Improve overall survival in metastatic hormone-sensitive prostate cancer when used with ADT, with or without docetaxel as indicated.
- Delay the development of metastatic disease in eligible patients.
- Help maintain disease control while continuing androgen deprivation therapy.
- Provide an oral androgen receptor inhibitor with limited penetration of the blood-brain barrier, a characteristic that may contribute to a lower incidence of certain central nervous system adverse effects compared with some other agents in its class.
Treatment response varies based on disease stage, prior therapies, and individual patient characteristics.
Important Safety Information and Side Effects
Nubeqa does not carry an FDA Boxed Warning.
Contraindications
The FDA Prescribing Information lists no contraindications for Nubeqa.
The most commonly reported adverse reactions include:
For non-metastatic castration-resistant prostate cancer (nmCRPC):
- Fatigue
- Pain in the arms, legs, hands, or feet
- Rash
For metastatic hormone-sensitive prostate cancer (mHSPC):
- Fatigue
- Rash
- Hypertension (high blood pressure)
- Increased liver enzymes (AST)
- Heart failure (reported more commonly in combination regimens)
- Neutropenia
Common laboratory abnormalities include:
- Increased bilirubin
- Increased AST
- Decreased neutrophil count
Patients should discuss the following risks with their healthcare provider:
- Ischemic heart disease
- Heart failure
- Increased risk of falls and fractures
- Embryo-fetal toxicity
- Elevated liver enzymes requiring appropriate clinical monitoring
- The importance of continuing androgen deprivation therapy throughout treatment
Patients should receive appropriate monitoring based on cardiovascular history and overall health.
Nubeqa is not indicated for use in women. Based on its mechanism of action, exposure during pregnancy may cause fetal harm. Male patients with female partners of reproductive potential should use effective contraception during treatment and for 1 week after the last dose.
Nubeqa is also not indicated for use during breastfeeding, and there are no data regarding its presence in human milk.
Healthcare providers should review all medications because clinically significant interactions may occur with:
- Breast cancer resistance protein (BCRP) substrates (such as rosuvastatin)
- Combined OATP1B1/OATP1B3 substrates
- Strong CYP3A4 inducers
- Certain P-glycoprotein (P-gp) substrates
Nubeqa is administered orally as 600 mg (two 300 mg tablets) twice daily and should be taken with food. Patients should continue androgen deprivation therapy unless they have undergone bilateral orchiectomy. If a dose is missed, it should be taken as soon as remembered before the next scheduled dose. Two doses should not be taken at the same time. Dose modifications may be necessary for certain adverse reactions or drug interactions.
Access to Multiple Medications
Support Beyond Nubeqa
Need more help with medication costs than just your oncology medication assistance?
Prescription Hope offers access to multiple medication assistance programs. Our list of hundreds of brand-name medications means no matter how many meds you qualify for, we can help.
Our service rate remains a reliable $70.00 per month, per medication.
Why Choose Prescription Hope
Patient-Focused Medication Support
Prescription Hope has coordinated with patient assistance programs to help patients save on their monthly medication costs for over 20 years. Our team of prescription assistance specialists advocates on your behalf and supports you throughout the application process and beyond.
Simplified Access to Prescription Medications
Our patient assistance services are a simple $70.00 per month, per medication. No hassles, hidden fees, add-on charges, or medication costs.
Ongoing Prescription Assistance
We don’t just help you apply for your patient assistance program. We continue to handle all the administrative tasks associated with your enrollment. Our team manages document and form updates, yearly renewals, program monitoring, issue resolution, and even takes care of your refill schedule.
Those who need Nubeqa assistance should enroll with Prescription Hope today to see how we can help you save on your monthly medication costs.